GlaxoSmithKline Infringes Antibody Patent: Genentech

Law360, New York (March 11, 2010, 4:46 PM EST) -- Genentech Inc. has fired back in a suit brought by GlaxoSmithKline PLC seeking to invalidate one of the biotechnology company's antibody patents, insisting that the drugmaker has committed infringement through the sale of cancer treatment Arzerra.

Genentech filed its response and counterclaims Wednesday in the U.S. District Court for the Northern District of California in a declaratory judgment suit brought by GSK that contends the patent-in-suit is invalid, unenforceable and not infringed by Arzerra.

San Fransisco-based Genentech also filed a motion seeking a transfer of the...
To view the full article, register now.